Summary: Non-invasive focused ultrasound appears to be beneficial in the treatment of Parkinson’s disease for patients whose symptoms are poorly controlled by traditional medications.
Source: University of Virginia
A scalpel-free alternative to brain surgery has the potential to benefit people with Parkinson’s disease symptoms that are much more severe on one side of the body, new research suggests.
More testing is needed, but the approach, which uses a technology called focused ultrasound, could offer a new option for patients whose symptoms are poorly controlled by medications and those who cannot or do not wish to undergo traditional brain surgery.
“This small brain region, the subthalamic nucleus, had a very strong and potent effect on parkinsonian symptoms when we targeted it with precise, focused ultrasound energy,” said researcher Jeff Elias, MD, a neurosurgeon at UVA Health and a pioneer in the field of focused ultrasound. “The key for the ultimate adoption of this new procedure will be further refinements of the technology to ensure reliability and safety.”
About Focused Ultrasound
Focused ultrasound offers a minimally invasive alternative to traditional surgery approaches. The technology focuses sound waves inside the body, much like a magnifying glass focuses light. This allows doctors to interrupt faulty brain circuits or destroy unwanted tissue. Magnetic-resonance imaging (MRI) allows doctors to monitor the procedure in real time – and to make adjustments as needed to obtain the best patient outcomes.
To determine if the technology could benefit patients with “asymmetrical” Parkinson’s symptoms, Elias and Binit Shah, MD, from UVA’s Department of Neurology, collaborated with Spain’s Centro Intregral de Neurociencias to evaluate the approach in 40 volunteers in a randomized, double-blinded study. Twenty-seven study participants received treatment with focused ultrasound, while 13 others received a simulated treatment, so that the researchers could compare the results between the real procedure and the placebo. The average age of study participants was 57.
The volunteers’ symptoms before and after the procedure were assessed on a scale of 1-44. Those who received the focused ultrasound procedure saw an improvement of 10 points, while those who received the sham treatment saw a difference of less than two points.
The study also looked at the safety of the procedure. Side effects included unwanted movements, muscle weakness, speech disturbances and difficulty walking. In most cases, these were temporary, but some effects persisted in six patients a year later.
The results warrant additional studies in larger numbers of volunteers conducted over longer periods of time, the researchers conclude.
“Parkinson’s disease affects patients in more ways than just tremor,” Shah said. “The current FDA approval for focused ultrasound in Parkinson’s disease treats only tremor. Targeting this new area allows us to improve tremor but also get more overall benefit for our patients than we previously were able to achieve.”
About UVA’s Focused Ultrasound Research
UVA has been at the leading edge of research into the technology’s potential to treat disease. For example, the federal Food and Drug Administration approved focused ultrasound for the treatment of essential tremor, a common movement disorder, based on Elias’ pioneering research. His work also paved the way for the FDA to authorize the technology to treat tremors caused by Parkinson’s disease.
Other researchers at UVA are investigating the technology’s potential to treat a wide variety of conditions, including epilepsy and breast cancer.
Elias and his colleagues have published their latest findings in the prestigious New England Journal of Medicine. The research team consisted of Raúl Martínez-Fernández, Jorge U. Máñez-Miró, Rafael Rodríguez-Rojas, Marta del Álamo, Binit B. Shah, Frida Hernández-Fernández, Jose A. Pineda-Pardo, Mariana H.G. Monje, Beatriz Fernández-Rodríguez, Scott A. Sperling, David Mata-Marín, Pasqualina Guida, Fernando Alonso-Frech, Ignacio Obeso, Carmen Gasca-Salas, Lydia Vela-Desojo, Elias and Jose A. Obeso.
Funding: The research was supported by InSightec, the manufacturer of the focused ultrasound technology; Charlottesville’s Focused Ultrasound Foundation, a longtime supporter of UVA’s focused ultrasound research; Fundación MAPFRE in Madrid; Fundación Hospitales de Madrid; and a University of Virginia Center of Excellence grant. Elias disclosed that his department at UVA has received research funding from InSightec, but the company had no role in the study design or analysis. A full list of author disclosures is included in the paper in the New England Journal of Medicine.
About this Parkinson’s disease research news
Source: University of Virginia
Contact: Josh Barney – University of Virginia
Image: The image is in the public domain
Original Research: Closed access.
“Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease” by Raúl Martínez-Fernández, M.D., Ph.D., Jorge U. Máñez-Miró, M.D., Rafael Rodríguez-Rojas, Ph.D., Marta del Álamo, M.D., Binit B. Shah, M.D., Frida Hernández-Fernández, M.Sc., José A. Pineda-Pardo, Ph.D., Mariana H.G. Monje, M.D., Ph.D., Beatriz Fernández-Rodríguez, M.D., Scott A. Sperling, Psy.D., David Mata-Marín, M.Sc., Pasqualina Guida, M.Sc., et al. NEJM
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinson’s Disease
The subthalamic nucleus is the preferred neurosurgical target for deep-brain stimulation to treat cardinal motor features of Parkinson’s disease. Focused ultrasound is an imaging-guided method for creating therapeutic lesions in deep-brain structures, including the subthalamic nucleus.
We randomly assigned, in a 2:1 ratio, patients with markedly asymmetric Parkinson’s disease who had motor signs not fully controlled by medication or who were ineligible for deep-brain stimulation surgery to undergo focused ultrasound subthalamotomy on the side opposite their main motor signs or a sham procedure. The primary efficacy outcome was the between-group difference in the change from baseline to 4 months in the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor score (i.e., part III) for the more affected body side (range, 0 to 44, with higher scores indicating worse parkinsonism) in the off-medication state. The primary safety outcome (procedure-related complications) was assessed at 4 months.
Among 40 enrolled patients, 27 were assigned to focused ultrasound subthalamotomy (active treatment) and 13 to the sham procedure (control). The mean MDS-UPDRS III score for the more affected side decreased from 19.9 at baseline to 9.9 at 4 months in the active-treatment group (least-squares mean difference, 9.8 points; 95% confidence interval [CI], 8.6 to 11.1) and from 18.7 to 17.1 in the control group (least-squares mean difference, 1.7 points; 95% CI, 0.0 to 3.5); the between-group difference was 8.1 points (95% CI, 6.0 to 10.3; P<0.001). Adverse events in the active-treatment group were dyskinesia in the off-medication state in 6 patients and in the on-medication state in 6, which persisted in 3 and 1, respectively, at 4 months; weakness on the treated side in 5 patients, which persisted in 2 at 4 months; speech disturbance in 15 patients, which persisted in 3 at 4 months; facial weakness in 3 patients, which persisted in 1 at 4 months; and gait disturbance in 13 patients, which persisted in 2 at 4 months. In 6 patients in the active-treatment group, some of these deficits were present at 12 months.
Focused ultrasound subthalamotomy in one hemisphere improved motor features of Parkinson’s disease in selected patients with asymmetric signs. Adverse events included speech and gait disturbances, weakness on the treated side, and dyskinesia. (Funded by Insightec and others; ClinicalTrials.gov number, NCT03454425. opens in new tab.)